Company Revenue

The company's orthopedic sales grew in the mid-single-digits for 2023 but were hamstrung by supply constraints and headwinds in China....

The company's orthopedic sales grew in the mid-teens for 2023 and is likely to be a $1 billion recon player...

The company finished 2023 with reported sales growth over 50% as it works to integrate NuVasive and reach a steady...

Healthy end markets and a robust innovation pipeline drove mid-single-digit growth for the company in 2023....

The company grew in the mid-teens for 2023 but can't fully go on offense until it resolves its supply chain...

The company's orthopedic sales grew nearly 10% in 2023, driven by strong procedure demand, leadership in robotics and momentum in...

The company grew in the mid-single-digits in 2023 as new products and recovering markets fueled its rebound to pre-COVID levels....

The company grew in the mid-teens in 3Q23 and sees competitors putting less focus on treating pediatric trauma and deformity....

The company notched its fifth consecutive quarter with more than 20% growth and is on track for arthroscopic MACI delivery...

The company grew 61% as-reported in the third quarter of 2023, or 1.2% on a pro forma basis including prior...